Disease Course in an IBD Cohort in the Era of Biological Treatment

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Ferring Pharmaceuticals
Merck
Information provided by (Responsible Party):
Marianne Vester-Andersen, Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT01468090
First received: November 7, 2011
Last updated: November 9, 2011
Last verified: November 2011

November 7, 2011
November 9, 2011
October 2011
June 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01468090 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Disease Course in an IBD Cohort in the Era of Biological Treatment
Disease Course in an IBD Cohort in the Era of Biological Treatment. Characterization of Early Predictors of Outcome and Identification of Patients in Early Need of Biological Treatment Based on an Unselected Consecutive Cohort After Seven Years Follow-up

The aim of the study is to do a 7-year follow-up of a consecutive inception cohort of 562 adults and children diagnosed and registered with inflammatory bowel disease in 2003-04 in order to evaluate the consequences of biological therapy in the treatment of IBD. The cohort is established after the implementation of biological agents in the treatment of IBD and the investigators hypothesis is that a) Severe disease course in IBD can be predicted by phenotypic presentation by serological, genetic, clinical and endoscopic characteristics to be used as guidance in the selection of treatment strategy and b) Introduction of biological treatment changes the course of disease in IBD and reduces the need of surgical procedures.

Methods: Medical records will be reviewed to register the use of medication, flare ups (medical and surgical) and hospital admissions. Diagnosis, disease localization and behavior will be evaluated. At outpatient visits patients will get a clinical examination, blood and faeces will be collected to biobank and patients will be offered an endoscopical examination. The Montreal classification, The Harvey & Bradshaw's activity index (CD) and the SCAAI score (UC) will be used to describe disease localization, extent, behavior and severity. An electronic database will be established in use of processing data.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Whole blood and faeces will be retained for biobank

Non-Probability Sample

562 patients diagnosed with Crohn's disease, Ulcerative colitis or indeterminant colitis in 2003-2004 i Copenhagen City and County and registered in a database.

  • Crohn's Disease
  • Ulcerative Colitis
Not Provided
Disease course
562 patients diagnosed with Crohn's disease (209), ulcerative colitis (326) or indeterminant colitis (27) in the period of 1st of January 2003 to 31st of December 2004 in Copenhagen City and County (an area covering 23% of the Danish population).
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
562
April 2014
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients wil be followed up and diagnosis will be reassessed.

Exclusion Criteria:

  • Non-IBD (after reassessing diagnosis)
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01468090
562_2003_2004
No
Marianne Vester-Andersen, Hvidovre University Hospital
Hvidovre University Hospital
  • Ferring Pharmaceuticals
  • Merck
Principal Investigator: Marianne Vester-Andersen, MD Dep. of Gastroenterology 360, Hvidovre Hospital
Study Chair: Pia Munkholm, ass. prof. DMsc Dep. of Gastroenterology, Herlev Hospital
Study Chair: Ida Vind, MD, PhD Dep. of gastroenterology, Amager Hospital
Study Director: Flemming Bendtsen, prof. DMsci Gastroenheden 360 Hvidovre University Hospital
Hvidovre University Hospital
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP